More clinical lessons from the FIELD study

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes. Results and discussion: Reduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11%), but only significant for total CVD events (p∈=∈0.035). The benefit of fenofibrate treatment was greater in patients with mixed dyslipidaemia, especially in those with triglycerides >2.3 mmol/L and low plasma levels of high-density lipoprotein cholesterol (relative risk reduction 27%, p∈=∈0.005). There were also microvascular benefits associated with fenofibrate treatment, specifically reduction in the rate of laser therapy for retinopathy (by 30%, p∈

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalCardiovascular Drugs and Therapy
Volume23
Issue number3
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Fenofibrate
Risk Reduction Behavior
Cardiovascular Diseases
Laser Therapy
Dyslipidemias
Type 2 Diabetes Mellitus
HDL Cholesterol
Triglycerides
Therapeutics

Keywords

  • Cardiovascular disease
  • Fenofibrate
  • FIELD
  • Retinopathy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

More clinical lessons from the FIELD study. / Fazio, Sergio.

In: Cardiovascular Drugs and Therapy, Vol. 23, No. 3, 06.2009, p. 235-241.

Research output: Contribution to journalArticle

@article{c022ad019b554dc8991333c00775c092,
title = "More clinical lessons from the FIELD study",
abstract = "Introduction: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes. Results and discussion: Reduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11{\%}), but only significant for total CVD events (p∈=∈0.035). The benefit of fenofibrate treatment was greater in patients with mixed dyslipidaemia, especially in those with triglycerides >2.3 mmol/L and low plasma levels of high-density lipoprotein cholesterol (relative risk reduction 27{\%}, p∈=∈0.005). There were also microvascular benefits associated with fenofibrate treatment, specifically reduction in the rate of laser therapy for retinopathy (by 30{\%}, p∈",
keywords = "Cardiovascular disease, Fenofibrate, FIELD, Retinopathy, Type 2 diabetes",
author = "Sergio Fazio",
year = "2009",
month = "6",
doi = "10.1007/s10557-008-6160-5",
language = "English (US)",
volume = "23",
pages = "235--241",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - More clinical lessons from the FIELD study

AU - Fazio, Sergio

PY - 2009/6

Y1 - 2009/6

N2 - Introduction: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes. Results and discussion: Reduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11%), but only significant for total CVD events (p∈=∈0.035). The benefit of fenofibrate treatment was greater in patients with mixed dyslipidaemia, especially in those with triglycerides >2.3 mmol/L and low plasma levels of high-density lipoprotein cholesterol (relative risk reduction 27%, p∈=∈0.005). There were also microvascular benefits associated with fenofibrate treatment, specifically reduction in the rate of laser therapy for retinopathy (by 30%, p∈

AB - Introduction: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study investigated the effect of fenofibrate treatment in 9,795 patients with type 2 diabetes. Results and discussion: Reduction in major coronary events (the primary endpoint) and total cardiovascular disease (CVD) events (the secondary endpoint) was similar (relative risk reduction 11%), but only significant for total CVD events (p∈=∈0.035). The benefit of fenofibrate treatment was greater in patients with mixed dyslipidaemia, especially in those with triglycerides >2.3 mmol/L and low plasma levels of high-density lipoprotein cholesterol (relative risk reduction 27%, p∈=∈0.005). There were also microvascular benefits associated with fenofibrate treatment, specifically reduction in the rate of laser therapy for retinopathy (by 30%, p∈

KW - Cardiovascular disease

KW - Fenofibrate

KW - FIELD

KW - Retinopathy

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=67649128495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649128495&partnerID=8YFLogxK

U2 - 10.1007/s10557-008-6160-5

DO - 10.1007/s10557-008-6160-5

M3 - Article

VL - 23

SP - 235

EP - 241

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -